News of Note—Inovio's MERS vaccine, Inimmune's NIH grant and more

non
(Pixabay)

Here is some other vaccine news of note for the week:

> In a phase 1 study, Inovio and GeneOne Life Science's MERS vaccine, dubbed INO-4700, induced high levels of antibody responses in roughly 95% of subjects and generated broad-based T-cell responses in nearly 90% of study participants. Release

> The University of Montana and startup Inimmune landed a $5.4 million grant from the NIH to develop a vaccine to fight the P. aeruginosa bacteria. Missoula Current article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

> Allergy Therapeutics’ grass pollen allergy vaccine Pollinex Quattro Grass showed significant and long-lasting symptom improvements three to six years after cessation of treatment. Precision Vaccinations article

 

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

Ad Environment Matters for Message Receptivity

After the U.K.'s nod for Pfizer's vaccine, NIAID Director Anthony Fauci argues the country’s regulators acted too quickly.